Optimal implementation of the 2019 ESC/EAS dyslipidaemia guidelines in patients with and without atherosclerotic cardiovascular disease across Europe: a simulation based on the DA VINCI study-Reference-Cited by-同舟云学术

Optimal implementation of the 2019 ESC/EAS dyslipidaemia guidelines in patients with and without atherosclerotic cardiovascular disease across Europe: a simulation based on the DA VINCI study

Published:2023-08 Issue: Volume:31 Page:100665
ISSN:2666-7762
Container-title:The Lancet Regional Health - Europe
language:en
Short-container-title:The Lancet Regional Health - Europe

Author:

Brandts Julia,Bray Sarah,Villa Guillermo,Catapano Alberico L.,Poulter Neil R.,Vallejo-Vaz Antonio J.,Ray Kausik K.^ORCID

Publisher

Elsevier BV

Subject

Health Policy,Oncology,Internal Medicine

Reference30 articles.

1. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk;Mach;Eur Heart J,2020

2. Pharmaceutical strategies for reducing LDL-C and risk of cardiovascular disease;Catapano;Atherosclerosis Suppl,2019

3. EU-wide cross-sectional observational study of lipid-modifying therapy use in secondary and primary care: the DA VINCI study;Ray;Eur J Prev Cardiol,2021

4. Current lipid lowering treatment and attainment of LDL targets recommended by ESC/EAS guidelines in very high-risk patients with established atherosclerotic cardiovascular disease: insights from the START registry;De Luca;Int J Cardiol,2020

5. Achievement of LDL-C targets defined by ESC/EAS (2011) guidelines in risk-stratified Korean patients with dyslipidemia receiving lipid-modifying treatments;Yang;Endocrinol Metab (Seoul),2020

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Intensive early and sustained lowering of non–high-density lipoprotein cholesterol after myocardial infarction and prognosis: the SWEDEHEART registry;European Heart Journal;2024-09-01

2. Obicetrapib on top of maximally tolerated lipid‐modifying therapies in participants with or at high risk for atherosclerotic cardiovascular disease: rationale and designs of BROADWAY and BROOKLYN;American Heart Journal;2024-08

3. Use of combination therapy is associated with improved LDL cholesterol management: 1-year follow-up results from the European observational SANTORINI study;European Journal of Preventive Cardiology;2024-06-11

4. Validation of the Novel Web-Based Application HUMTELEMED for a Comprehensive Assessment of Cardiovascular Risk Based on the 2021 European Society of Cardiology Guidelines;Journal of Clinical Medicine;2024-04-16

5. Secondary Cardiovascular Disease Prevention Deficit Persists over the Years: A Multicenter Cross-Sectional Study Involving 1003 Consecutive Patients from Greece;Endocrines;2024-03-27